生工生物全资收购曙芯生物

Core Viewpoint - The acquisition marks a significant milestone for Shenggong Bio, completing its full industry chain layout from "automation equipment - core raw materials - reagent consumables - technical services" for independent control [1][4]. Group 1: Acquisition Details - Shenggong Bio has officially announced the full acquisition of core assets and personnel from Shenzhen Shuxin Biotechnology Co., Ltd. This acquisition is a crucial step in the company's domestic layout of the synthetic biology industry chain [2]. - The acquisition represents a deep integration of two major strengths in the domestic life sciences field, which will drive a transformation in the market landscape for high-end synthetic equipment and high-throughput synthesis technology [2]. Group 2: New Department Formation - The newly formed High-Core Synthesis Department will leverage Shenggong Bio's large-scale production capacity, nationwide service network, and comprehensive supply chain system. It aims to integrate the team's equipment R&D capabilities, AI algorithm advantages, and core technologies [3]. - The department will focus on the "bottleneck" areas of the upstream synthetic biology industry, creating a comprehensive platform for domestic high-end synthetic equipment and technical services that encompasses R&D, production, sales, and service [3]. Group 3: Product Matrix - The company plans to gradually establish a complete product matrix centered around high-throughput chip DNA synthesizers and automated bacterial selection instruments. This will include customized biological chip synthesis CRO services and supporting reagent consumables [3]. - The goal is to meet user needs throughout the entire process from DNA synthesis to strain selection [3].